Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
m |
||
| Line 1: | Line 1: | ||
{| class="wikitable" style="text-align:center; width:50%;" | {| class="wikitable" style="text-align:center; width:50%;" | ||
| − | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:# | + | ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26" |'''Section editor''' |
|- | |- | ||
| style="background-color:#F0F0F0; width:15%" |[[File:MartinSchoen.jpg|frameless|upright=0.3|center]] | | style="background-color:#F0F0F0; width:15%" |[[File:MartinSchoen.jpg|frameless|upright=0.3|center]] | ||
| − | | style="width:35%" |<big>[[User:Marteens|Martin W. Schoen, MD, MPH]]<br>Saint Louis University<br>St. Louis, MO</big> | + | | style="width:35%" |<big>[[User:Marteens|Martin W. Schoen, MD, MPH]]<br>Saint Louis University<br>St. Louis, MO</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]][https://twitter.com/mwschoen mwschoen] |
|- | |- | ||
|} | |} | ||
Revision as of 02:12, 30 April 2019
| Section editor | |
|---|---|
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO  mwschoen
|
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Frankel et al. 2014 | Phase I/II, <20 pts |
Chemotherapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed